<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850160</url>
  </required_header>
  <id_info>
    <org_study_id>005-12 HTA</org_study_id>
    <nct_id>NCT01850160</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension</brief_title>
  <official_title>Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farma de Colombia SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farma de Colombia SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy&#xD;
      with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of&#xD;
      adult patients with diagnosis of arterial hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In spite of the existence of a great variety of treatments with drugs effective against&#xD;
      arterial hypertension, the percentages of arterial hypertension control with monotherapy&#xD;
      remain quite low reason why the fixed-dose combinations of drugs have been one of the most&#xD;
      interesting research topics in order to achieve an appropriate control of arterial&#xD;
      hypertension.&#xD;
&#xD;
      The possibility of achieving better coverage and Blood Pressure control through a drug&#xD;
      combination has leaded, on a scientific base of the efficacy of an Angiotensin Receptor&#xD;
      Blockers II plus diuretic combination, to the development of a great number of combinations&#xD;
      with different Angiotensin II Receptor Blockers plus hydrochlorothiazide. Yet it is&#xD;
      noteworthy that despite the increasing evidence showing additional benefits in Blood pressure&#xD;
      control and reduction of cardiovascular outcomes with chlorthalidone over&#xD;
      hydrochlorothiazide, there is neither a great number of combinations nor studies with&#xD;
      Angiotensin II Receptor Blockers plus chlorthalidone whereby the conduction of a trial&#xD;
      assessing the efficacy and safety of Valsartan plus chlorthalidone in hypertensive patients&#xD;
      is proposed plus the benefits of combination therapy that include, among others, the greater&#xD;
      efficacy with lower doses of each individual component as well as reduction in occurrence of&#xD;
      adverse events directly related with lower drug doses.With this treatment schedule it is&#xD;
      expected to obtain higher control of blood pressure values and greater percentage of&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Systolic and Diastolic Blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes in Systolic and Diastolic Blood Pressure from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Systolic blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes of systolic blood pressure from baseline up to week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Diastolic blood pressure values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes of diastolic blood pressure from baseline up to week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of diastolic blood pressure in arterial blood pressure median values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the changes in diastolic blood pressure in Arterial Blood Pressure Media from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of systolic blood pressure values in arterial blood pressure median values</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the change in systolic blood pressure in Arterial Blood Pressure Median from baseline up to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient that achieving blood pressure values lower than 140/90 (systolic/diastolic) at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving blood pressure values lower than 140/90 (systolic/diastolic) at weeks 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients that achieving systolic blood pressure values lower than 140 at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving systolic blood pressure lower than 140 at weeks 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients that achieving diastolic blood pressure values lower than 90 at week 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of patients achieving diastolic blood pressure lower than 90 at week 6 and 12</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic changes secondary to the treatment with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Identify if there are significant differences regarding metabolic changes secondary to the treatment with Valsartan and Chlorthalidone Vs Valsartan or Chlorthalidone.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events in each intervention group</measure>
    <time_frame>12 weeks</time_frame>
    <description>Determine the percentage of incidence of adverse events in each intervention group.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>GROUP A: Valsartan plus Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP B: Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP C: Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP A: Valsartan plus Chlorthalidone</intervention_name>
    <description>Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.</description>
    <arm_group_label>GROUP A: Valsartan plus Chlorthalidone</arm_group_label>
    <other_name>Chlorthalidone Drug Combination</other_name>
    <other_name>Valsartan Drug Combination</other_name>
    <other_name>Antihypertensive Agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP B: Valsartan</intervention_name>
    <description>GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.</description>
    <arm_group_label>GROUP B: Valsartan</arm_group_label>
    <other_name>Angiotensin II Receptor Antagonist</other_name>
    <other_name>Antihypertensive Agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GROUP C: Chlorthalidone</intervention_name>
    <description>GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.</description>
    <arm_group_label>GROUP C: Chlorthalidone</arm_group_label>
    <other_name>Sodium Chloride Symporter Inhibitors</other_name>
    <other_name>Antihypertensive Agents</other_name>
    <other_name>Diuretics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with diagnosis of arterial hypertension defined as:&#xD;
&#xD;
          -  Systolic blood pressure greater or equal to 140 and lower than 180 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure greater or equal to 90 and lower than 110 mmHg&#xD;
&#xD;
          -  Non controlled patients with antihypertensive treatment (blood pressure values:&#xD;
             Systolic blood pressure &gt; 140 mmHg and/or Diastolic blood pressure &gt; 90 mmHg) or&#xD;
             patients antihypertensive treatment-naïve.&#xD;
&#xD;
          -  Likelihood of attending consultations according to the trial chronogram.&#xD;
&#xD;
          -  Informed Consent Signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of severe or malignant arterial hypertension defined as:&#xD;
&#xD;
          -  Systolic blood pressure greater or equal to 180 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure greater or equal to 110 mmHg&#xD;
&#xD;
          -  Patients with secondary arterial hypertension of any etiology.&#xD;
&#xD;
          -  Pregnant women or women with childbearing potential who are not using appropriate&#xD;
             contraception methods; women planning to become pregnant during the trial.&#xD;
&#xD;
          -  Patients with history of Acute Myocardial Infarction o Angina Pectoris within the 6&#xD;
             months prior to the trial initiation.&#xD;
&#xD;
          -  Diagnosis of Cerebrovascular Disease (CVD) o Transient Ischemic Attack (TIA) within&#xD;
             the 6 previous months.&#xD;
&#xD;
          -  Patients with Severe Renal Disease defined by serum Creatinine levels higher than 1.5&#xD;
             mg/dl.&#xD;
&#xD;
          -  Diagnosed or suspected unilateral or bilateral renal artery stenosis.&#xD;
&#xD;
          -  History of non remitting cancer within the 5 years prior to the trial initiation.&#xD;
&#xD;
          -  Patients with Hypokalemia or Hyperkalemia.&#xD;
&#xD;
          -  Patients receiving Valsartan or Chlortalidone during the 14 previous days.&#xD;
&#xD;
          -  Patients with known hypersensitivity to Valsartan or Chlorthalidone.&#xD;
&#xD;
          -  Unstable patients with antecedent of hospitalization within the 4 days prior to their&#xD;
             enrollment in the trial.&#xD;
&#xD;
          -  Patients with history of drugs and alcohol abuse within the last year.&#xD;
&#xD;
          -  Patients who have taken part in other clinical trial within the 4 weeks prior to the&#xD;
             initiation of this research.&#xD;
&#xD;
          -  Patients with any other clinical condition that the investigator deems may affect the&#xD;
             patient follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan D Romero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Farma de Colombia SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Diagnostico Cardiologico</name>
      <address>
        <city>Cartagena</city>
        <state>Bolivar</state>
        <zip>130001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiomet Cequin</name>
      <address>
        <city>Armenia</city>
        <state>Quindio</state>
        <zip>630001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPlus</name>
      <address>
        <city>Bogota DC</city>
        <zip>11001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro AMCOR</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico quirurgico</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro médico de hipertensión arterial</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica DAME</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Edificio Novoa</name>
      <address>
        <city>Quito</city>
        <zip>EC170150</zip>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Ecuador</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>Drug therapy combination</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Chlorthalidone</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

